Cytovation
Clinical stage immune-oncology company focused on the development of its targeted tumor membrane immunotherapy
Bergen, Norwaywww.cytovation.com ↗
Total raised
€25M
€25,191,626
Funding rounds
2
Investors
2
distinct backers
Active since
2022-01
latest 2023-06
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood30
base rate 44% for Series A
- ▼ Overdue vs cohort gap
- ▼ Down/flat last round
Exit likelihood12
base rate 12% (2+ rounds)
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-06-12 | Series A | €7.4M | Canica,Sandwater | View deal → |
| 2022-01-25 | Series A | €18M | Canica,Sandwater | View deal → |
Related news
- Cytovation Raises $20M in Series A Financingfinsmes.com · 2022-01
- arcticstartup.com
Similar companies
same sector or country- Visma€3.0BNorway · Software
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Adevinta€1.9BNorway · Marketing
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech